International urology and nephrology · 2011
Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moriyama Takahito, Tsuruta Yuki, Kojima Chiari, Itabashi Mitsuyo, Sugiura Hidekazu, Takei Takashi, Ogawa Tetsuya, Uchida Keiko, Tsuchiya Ken, Nitta Kosaku
Аннотация
BACKGROUND: Blockade of the renin-angiotensin-aldosterone system is a therapeutic mainstay in patients with chronic kidney disease (CKD). However, the renoprotective effect of the novel direct renin inhibitor aliskiren is unknown.
MATERIALS AND METHODS: We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment.
RESULTS: Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change.
CONCLUSIONS: Aliskiren combined with olmesartan reduces proteinuria in CKD patients.
MATERIALS AND METHODS: We performed a prospective study in 10 CKD patients. All 10 patients with persistent proteinuria (urinary protein-to-creatinin ratio 0.3-3.5 g/g), despite good blood pressure control (<130/80 mmHg) with olmesartan, were started on 150 mg/day aliskiren. Clinical parameters were examined before and after 4, 8, 12, and 16 weeks of treatment.
RESULTS: Urinary protein-to-creatinine ratio significantly decreased by about 40% at 16 weeks from baseline (P = 0.0002), although estimated glomerular filtration rate and blood pressure did not change throughout the study period. Plasma renin activity also decreased significantly from baseline (P = 0.019), although plasma aldosterone concentration did not change.
CONCLUSIONS: Aliskiren combined with olmesartan reduces proteinuria in CKD patients.
Предметные рубрики MeSH
AdultAldosteroneAmidesAnalysis of VarianceAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsBlood PressureCreatinineDrug Therapy, CombinationFemaleFumaratesGlomerular Filtration RateHumansImidazolesMaleMiddle AgedOlmesartan MedoxomilProteinuriaRenal Insufficiency, ChronicReninTetrazolesYoung AdultRenin Inhibitors